Healthcare AI oversight, US versus UK
By AI Resource Zone Admin · March 5, 2026 · 4 min read
Medical AI is regulated through existing device frameworks, but US and UK approaches to updates and transparency diverge.
Medical AI sits within the existing medical device frameworks in both the United States and the United Kingdom, rather than under standalone AI statutes. In the US, the Food and Drug Administration regulates software as a medical device, including machine learning models used for diagnosis, triage, or treatment recommendation. The agency has been developing a predetermined change control plan framework so that certain model updates can be pre-authorized rather than triggering a new submission each time.
In the UK, the Medicines and Healthcare products Regulatory Agency operates a parallel regime that has evolved since the country left the European Union's medical device system. The MHRA has published a program of work on software and AI as a medical device, covering pre-market assessment, post-market surveillance, and cybersecurity expectations. Collaboration between the MHRA, the National Institute for Health and Care Excellence, and NHS England produces joint guidance on evaluation and procurement, particularly for tools used within the National Health Service.
A practical difference between the two jurisdictions lies in deployment transparency. The FDA maintains a public list of AI- and machine learning-enabled medical devices that have received clearance or approval, updated periodically. The UK publishes some information through its device registration database and through NHS-specific evaluation frameworks such as the Digital Technology Assessment Criteria. Neither system, in its current state, offers a single patient-facing register of every AI tool touching their care.
Editor's note: Patients and clinicians would benefit from clearer labeling at the point of care, not only at market authorization. Knowing that a specific decision was informed or generated by an AI tool, and being able to ask about its intended use and known limits, is a modest demand that both systems could meet. The conversation about AI in medicine will be healthier when it moves from abstract promises to this level of concrete transparency.